Fatima Naseem, Srivastava Anand Narain, Nigam Jaya, Tandon Nishi, Ahmad Rumana, Kumar Vijay
Department of Pathology, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Department of Surgical Gastroenterology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Indian J Pathol Microbiol. 2019 Jul-Sep;62(3):384-390. doi: 10.4103/IJPM.IJPM_134_19.
Gallbladder cancer (GBC) is the most frequent biliary tract cancer, with high morbidity and poor prognosis, and shows early metastasis and invasiveness. No reliable biomarkers are available for detection of GBC progression.
To investigate the immunohistochemical expression of Oct-4 and CD133 in malignant and nonneoplastic lesions of gallbladder and to analyze the clinical significance of the expressions related to clinicopathological parameters.
This is a prospective case control study, conducted in medical college background.
A total of 103 cases of gallbladder were grouped into malignant lesions (n = 48) and nonneoplastic lesions (simple epithelial hyperplasia; n = 35 and chronic cholecystitis; n = 20). All tissue samples were evaluated for expression of Oct-4 and CD133 using immunohistochemistry in an effort to elucidate the correlation between their expressions with clinicopathological parameters.
The final score was calculated by multiplying the intensity to the percentage of positive cells. The scores ≥2 were considered as positive.
Significant positive correlation of higher expression levels of Oct-4 and CD133 were observed in malignant as compared to nonneoplastic lesions of gallbladder (P < 0.0001). High expression of Oct-4 and CD133 were significantly associated with tumor grading (Oct-4, P = 0.04; CD133, P = 0.02), staging (Oct-4, P = 0.03; CD133, P = 0.02), and liver metastasis (Oct-4, P = 0.01; CD133, P = 0.007). Significantly reduced survival was observed with high expression of Oct-4 (P = 0.002). No significant correction was observed between CD 133 and survival.
This study revealed that high expression level of Oct-4 may provide a new insight for the prognosis of the disease in terms of clinical staging and grade.
胆囊癌（GBC）是最常见的胆道癌，发病率高且预后差，具有早期转移和侵袭性。目前尚无可靠的生物标志物可用于检测胆囊癌的进展。
研究Oct-4和CD133在胆囊恶性和非肿瘤性病变中的免疫组化表达，并分析其表达与临床病理参数相关的临床意义。
这是一项在医学院背景下进行的前瞻性病例对照研究。
总共103例胆囊病例分为恶性病变组（n = 48）和非肿瘤性病变组（单纯上皮增生；n = 35和慢性胆囊炎；n = 20）。所有组织样本均采用免疫组化法评估Oct-4和CD133的表达，以阐明其表达与临床病理参数之间的相关性。
最终得分通过将强度乘以阳性细胞百分比来计算。得分≥2被视为阳性。
与胆囊非肿瘤性病变相比，恶性病变中Oct-4和CD133的高表达存在显著正相关（P < 0.0001）。Oct-4和CD133的高表达与肿瘤分级（Oct-4，P = 0.04；CD133，P = 0.02）、分期（Oct-4，P = 0.03；CD133，P = 0.02）和肝转移（Oct-4，P = 0.01；CD133，P = 0.007）显著相关。Oct-4高表达者生存率显著降低（P = 0.002）。CD133与生存率之间未观察到显著相关性。
本研究表明，Oct-4的高表达水平可能为该疾病的临床分期和分级预后提供新的见解。
